Last week I had the pleasure of spending a few days in Boston attending two separate life science events, Device Talks and McDermott Will & Emery’s Life Sciences Dealmaking Symposium. Although I love spending time in Boston, which is booming, I wish these events had been another week as I was not at home for … Continue reading Device Talks Boston – A Recap
One of the most common questions I get asked comes from Pre-Clinical Life Science companies is why do I need insurance? I agree that pre-clinical life science companies have about as little risk as a company can have. Why they need insurance really comes down to contracts, investors and statutory regulations. If the company enters … Continue reading Common Question Friday – Why Do Pre-Clinical Companies Need Insurance?
Last week the issue of public companies having to do quarterly reports popped up in the news in a big way with the President tweeting and then speaking on the possibility of ending quarterly reporting. There are a lot of opinions out there on whether this is a good idea or bad idea. Some people … Continue reading How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market
I recently read that Illinois Tool Works (ITW) prevailed in a case against the IRS. The IRS challenged that a loan from ITW’s foreign subsidiary to its parent company was a nontaxable return of capital as ITW contended. The IRS dtermined that it was not a loan but a dividend and as a result a … Continue reading Not Sure The IRS Agrees With a Tax Position Your Company Has Taken? Here is a Solution
Skin in the game – that means your insurance broker actually having a vested interest in your success and the level of service you receive year in and year out. Skin in the game does not mean your broker having a greater financial interest in year one compared to subsequent years yet that is how … Continue reading Your Insurance Broker Has No Incentive to Retain You as a Client!!!!
Cornerstone Research always puts out great data and this report on Securities Class Action Filings for the first half of 2018 is no exception. I recommend you check out the full report which you can find here. These visuals really speak for themselves but the big takeaway is that if you are publicly traded company … Continue reading Why Securities Class Filings are a Reality for Publicly Traded Companies
Welcome to a new work week, the final couple of days of July. Here is what I'm reading this morning: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs (Benzinga) Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually (Endpoints) 7 medtech stories we missed this … Continue reading Monday Morning Healthcare News